| Comment Record |
|
Commentor |
Mr. Joseph Zannoni |
Date/Time |
2003-03-21 12:31:07 |
|
Organization |
Jinke Group USA |
|
Category |
Dietary Supplement Industry |
| Comments for FDA General |
| Questions |
|
1. General Comments
|
Dear Sir,
I am an employee of the Beijing Gingko Group and its US subsidiary, Jinke Group USA.
Jinke Group USA is a primary manufacturer of finished botanical extracts, currently produced in 5 GMP facilities in China. We now market a range of pharmaceutical intermediates, botanical extracts and specialty value-added raw materials in Europe, Japan, Latin America and in China.
We believe that the agency can appropriately regulate ephedra under the current DESHEA regulations.
A departure from the intent of this regulation will confuse the consumer and dilute the meaning and intent of DESHEA. If taken properly, this plant extract has been shown to be very beneficial to many individuals and not harmful.
Sincerely,
Joseph M. Zannoni
VP Sales & Marketing
|
|